Literature DB >> 23184010

Interrelationship between haemodynamic state and serum intact parathyroid hormone levels in patients with chronic heart failure.

Tadafumi Sugimoto1, Kaoru Dohi, Katsuya Onishi, Kiyotaka Watanabe, Yuichi Sato, Emiyo Sugiura, Shiro Nakamori, Hiroshi Nakajima, Mashio Nakamura, Masaaki Ito.   

Abstract

OBJECTIVE: To assess the impact of serum intact parathyroid hormone (PTH) levels on haemodynamic state and their relations by comparing plasma B-type natriuretic peptide (BNP) levels.
DESIGN: Cross-sectional study in molecular epidemiology.
SETTING: Mie University Hospital, Tsu, Japan. PATIENTS: Consecutive 105 patients with chronic heart failure (CHF). MAIN OUTCOME MEASURES: Serum intact PTH and plasma BNP levels were assessed simultaneously with right heart catheterisation.
RESULTS: Although serum intact PTH levels (46±25 pg/ml) were within the normal range (<65 pg/ml) in 87% of patients, log-transformed intact PTH levels significantly correlated with pulmonary capillary wedge pressure (PCWP: 15±9 mm Hg, r=0.55, p<0.05) and heart rate (73±14/min, r=0.40, p<0.05), whereas log-transformed intact PTH levels were inversely correlated with stroke volume index (SVI: 38±11 ml/m(2), r=-0.52, p<0.05) and cardiac index (2.6±0.7 l/min/m(2), r=-0.41, p<0.05) in all patients. PCWP and SVI were independent determinants of log-transformed intact PTH levels (β=0.40 and -0.37, p<0.05, respectively) after adjusting for variables associated with PTH. Conversely, after adjusting for variables associated with CHF, log-transformed intact PTH levels were an independent determinant of PCWP, SVI, heart rate and cardiac index (β=0.38, -0.33, 0.32, and -0.25, p<0.05, respectively), and might be defined as a superior determinant of SVI and cardiac index compared with log-transformed BNP levels using stepwise multivariate regression analyses.
CONCLUSIONS: Increased PCWP and decreased SVI independently contribute to elevated intact PTH in patients with CHF.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23184010     DOI: 10.1136/heartjnl-2012-302779

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  6 in total

1.  Secondary hyperparathyroidism prevalence and prognostic role in elderly males with heart failure.

Authors:  G Loncar; B Bozic; N Cvetinovic; H-D Dungen; M Lainscak; S von Haehling; W Doehner; Z Radojicic; B Putnikovic; T Trippel; V Popovic
Journal:  J Endocrinol Invest       Date:  2016-10-13       Impact factor: 4.256

2.  Correlation between serum parathyroid hormone levels and coronary artery calcification in patients without renal failure.

Authors:  Gang-Yong Wu; Bai-Da Xu; Ting Wu; Xiao-Ying Wang; Tian-Xiao Wang; Xiao Zhang; Xiao Wang; Yang Xia; Gang-Jun Zong
Journal:  Biomed Rep       Date:  2016-09-26

3.  Association between circulating fibroblast growth factor 23, α-Klotho, and the left ventricular ejection fraction and left ventricular mass in cardiology inpatients.

Authors:  Kensaku Shibata; Shu-Ichi Fujita; Hideaki Morita; Yusuke Okamoto; Koichi Sohmiya; Masaaki Hoshiga; Nobukazu Ishizaka
Journal:  PLoS One       Date:  2013-09-09       Impact factor: 3.240

4.  Poststroke hip fracture: prevalence, clinical characteristics, mineral-bone metabolism, outcomes, and gaps in prevention.

Authors:  Alexander Fisher; Wichat Srikusalanukul; Michael Davis; Paul Smith
Journal:  Stroke Res Treat       Date:  2013-09-25

Review 5.  Neurohumoral Control of Sinoatrial Node Activity and Heart Rate: Insight From Experimental Models and Findings From Humans.

Authors:  Eilidh A MacDonald; Robert A Rose; T Alexander Quinn
Journal:  Front Physiol       Date:  2020-03-03       Impact factor: 4.566

6.  The association of secondary hyperparathyroidism and myocardial damages in hemodialysis end-stage renal disease patients: assessed by cardiovascular magnetic resonance native T1 mapping.

Authors:  Huayan Xu; Wanlin Peng; Zhigang Yang; Yingkun Guo; Yi Zhang; Chunchao Xia; Zhenlin Li; Rong Xu
Journal:  J Cardiovasc Magn Reson       Date:  2021-03-11       Impact factor: 5.364

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.